JP2017527615A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017527615A5 JP2017527615A5 JP2017531467A JP2017531467A JP2017527615A5 JP 2017527615 A5 JP2017527615 A5 JP 2017527615A5 JP 2017531467 A JP2017531467 A JP 2017531467A JP 2017531467 A JP2017531467 A JP 2017531467A JP 2017527615 A5 JP2017527615 A5 JP 2017527615A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- pharmaceutical composition
- composition according
- day
- fibrosis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000034 method Methods 0.000 claims description 43
- 239000008194 pharmaceutical composition Substances 0.000 claims description 26
- 206010016654 Fibrosis Diseases 0.000 claims description 21
- 230000004761 fibrosis Effects 0.000 claims description 21
- 239000003112 inhibitor Substances 0.000 claims description 19
- 206010028980 Neoplasm Diseases 0.000 claims description 18
- 201000011510 cancer Diseases 0.000 claims description 18
- 210000004500 stellate cell Anatomy 0.000 claims description 15
- 210000000651 myofibroblast Anatomy 0.000 claims description 12
- 239000000203 mixture Substances 0.000 claims description 11
- 201000010099 disease Diseases 0.000 claims description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 9
- 239000012634 fragment Substances 0.000 claims description 9
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 9
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 9
- 208000000668 Chronic Pancreatitis Diseases 0.000 claims description 7
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 7
- 206010033649 Pancreatitis chronic Diseases 0.000 claims description 7
- 108091000080 Phosphotransferase Proteins 0.000 claims description 7
- 230000003176 fibrotic effect Effects 0.000 claims description 7
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 7
- 108020004707 nucleic acids Proteins 0.000 claims description 7
- 102000039446 nucleic acids Human genes 0.000 claims description 7
- 150000007523 nucleic acids Chemical class 0.000 claims description 7
- 201000002528 pancreatic cancer Diseases 0.000 claims description 7
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 7
- 102000020233 phosphotransferase Human genes 0.000 claims description 7
- 201000003803 Inflammatory myofibroblastic tumor Diseases 0.000 claims description 6
- 206010067917 Inflammatory myofibroblastic tumour Diseases 0.000 claims description 6
- 238000013508 migration Methods 0.000 claims description 6
- 230000005012 migration Effects 0.000 claims description 6
- 230000002265 prevention Effects 0.000 claims description 5
- 150000003384 small molecules Chemical group 0.000 claims description 5
- 208000003174 Brain Neoplasms Diseases 0.000 claims description 4
- 102100031650 C-X-C chemokine receptor type 4 Human genes 0.000 claims description 4
- 208000011231 Crohn disease Diseases 0.000 claims description 4
- 101000922348 Homo sapiens C-X-C chemokine receptor type 4 Proteins 0.000 claims description 4
- 208000008839 Kidney Neoplasms Diseases 0.000 claims description 4
- 239000000427 antigen Substances 0.000 claims description 4
- 108091007433 antigens Proteins 0.000 claims description 4
- 102000036639 antigens Human genes 0.000 claims description 4
- 210000004027 cell Anatomy 0.000 claims description 4
- 208000029742 colonic neoplasm Diseases 0.000 claims description 4
- 230000000694 effects Effects 0.000 claims description 4
- 208000014018 liver neoplasm Diseases 0.000 claims description 4
- 208000020816 lung neoplasm Diseases 0.000 claims description 4
- 229920001184 polypeptide Polymers 0.000 claims description 4
- 230000001737 promoting effect Effects 0.000 claims description 4
- 238000001959 radiotherapy Methods 0.000 claims description 4
- 239000003795 chemical substances by application Substances 0.000 claims description 3
- 210000001519 tissue Anatomy 0.000 claims description 3
- 108091023037 Aptamer Proteins 0.000 claims description 2
- 239000003840 Bafetinib Substances 0.000 claims description 2
- 206010005003 Bladder cancer Diseases 0.000 claims description 2
- 206010006187 Breast cancer Diseases 0.000 claims description 2
- 208000026310 Breast neoplasm Diseases 0.000 claims description 2
- 201000009030 Carcinoma Diseases 0.000 claims description 2
- 206010008342 Cervix carcinoma Diseases 0.000 claims description 2
- 206010009944 Colon cancer Diseases 0.000 claims description 2
- 208000001708 Dupuytren contracture Diseases 0.000 claims description 2
- 206010019695 Hepatic neoplasm Diseases 0.000 claims description 2
- 208000024934 IgG4-related mediastinitis Diseases 0.000 claims description 2
- 208000014919 IgG4-related retroperitoneal fibrosis Diseases 0.000 claims description 2
- 206010072877 Intestinal fibrosis Diseases 0.000 claims description 2
- 208000002260 Keloid Diseases 0.000 claims description 2
- 206010023330 Keloid scar Diseases 0.000 claims description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 2
- 206010025323 Lymphomas Diseases 0.000 claims description 2
- 208000002805 Mediastinal fibrosis Diseases 0.000 claims description 2
- 206010027476 Metastases Diseases 0.000 claims description 2
- 206010030020 Occupational exposure to radiation Diseases 0.000 claims description 2
- 206010033128 Ovarian cancer Diseases 0.000 claims description 2
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 2
- 208000004362 Penile Induration Diseases 0.000 claims description 2
- 208000020758 Peyronie disease Diseases 0.000 claims description 2
- 206010036805 Progressive massive fibrosis Diseases 0.000 claims description 2
- 206010060862 Prostate cancer Diseases 0.000 claims description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 2
- 206010038389 Renal cancer Diseases 0.000 claims description 2
- 206010038979 Retroperitoneal fibrosis Diseases 0.000 claims description 2
- 206010039491 Sarcoma Diseases 0.000 claims description 2
- 206010039710 Scleroderma Diseases 0.000 claims description 2
- 108020004459 Small interfering RNA Proteins 0.000 claims description 2
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 2
- 201000009594 Systemic Scleroderma Diseases 0.000 claims description 2
- 206010042953 Systemic sclerosis Diseases 0.000 claims description 2
- 208000024770 Thyroid neoplasm Diseases 0.000 claims description 2
- 208000023915 Ureteral Neoplasms Diseases 0.000 claims description 2
- 206010046392 Ureteric cancer Diseases 0.000 claims description 2
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 2
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 2
- 239000000853 adhesive Substances 0.000 claims description 2
- 230000001070 adhesive effect Effects 0.000 claims description 2
- 239000005557 antagonist Substances 0.000 claims description 2
- 206010003246 arthritis Diseases 0.000 claims description 2
- ZGBAJMQHJDFTQJ-DEOSSOPVSA-N bafetinib Chemical group C1[C@@H](N(C)C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=NC=3)C(C)=CC=2)C=C1C(F)(F)F ZGBAJMQHJDFTQJ-DEOSSOPVSA-N 0.000 claims description 2
- 229950002365 bafetinib Drugs 0.000 claims description 2
- 210000000988 bone and bone Anatomy 0.000 claims description 2
- 210000000481 breast Anatomy 0.000 claims description 2
- 208000025997 central nervous system neoplasm Diseases 0.000 claims description 2
- 201000010881 cervical cancer Diseases 0.000 claims description 2
- 238000002512 chemotherapy Methods 0.000 claims description 2
- 208000037976 chronic inflammation Diseases 0.000 claims description 2
- 230000006020 chronic inflammation Effects 0.000 claims description 2
- 208000019425 cirrhosis of liver Diseases 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 206010017758 gastric cancer Diseases 0.000 claims description 2
- 201000010536 head and neck cancer Diseases 0.000 claims description 2
- 208000014829 head and neck neoplasm Diseases 0.000 claims description 2
- 208000024348 heart neoplasm Diseases 0.000 claims description 2
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims description 2
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims description 2
- 210000001117 keloid Anatomy 0.000 claims description 2
- 201000010982 kidney cancer Diseases 0.000 claims description 2
- 201000007270 liver cancer Diseases 0.000 claims description 2
- 201000005202 lung cancer Diseases 0.000 claims description 2
- 208000037841 lung tumor Diseases 0.000 claims description 2
- 210000001165 lymph node Anatomy 0.000 claims description 2
- 210000001370 mediastinum Anatomy 0.000 claims description 2
- 201000001441 melanoma Diseases 0.000 claims description 2
- 230000009401 metastasis Effects 0.000 claims description 2
- 206010028537 myelofibrosis Diseases 0.000 claims description 2
- 210000000496 pancreas Anatomy 0.000 claims description 2
- 102000004169 proteins and genes Human genes 0.000 claims description 2
- 108090000623 proteins and genes Proteins 0.000 claims description 2
- 208000005069 pulmonary fibrosis Diseases 0.000 claims description 2
- 210000003079 salivary gland Anatomy 0.000 claims description 2
- 210000000813 small intestine Anatomy 0.000 claims description 2
- 210000000952 spleen Anatomy 0.000 claims description 2
- 201000011549 stomach cancer Diseases 0.000 claims description 2
- 238000001356 surgical procedure Methods 0.000 claims description 2
- 230000009885 systemic effect Effects 0.000 claims description 2
- 201000002510 thyroid cancer Diseases 0.000 claims description 2
- 210000001685 thyroid gland Anatomy 0.000 claims description 2
- 201000011294 ureter cancer Diseases 0.000 claims description 2
- 210000003932 urinary bladder Anatomy 0.000 claims description 2
- 201000005112 urinary bladder cancer Diseases 0.000 claims description 2
- 230000005764 inhibitory process Effects 0.000 claims 2
- 239000012829 chemotherapy agent Substances 0.000 claims 1
- 238000007918 intramuscular administration Methods 0.000 claims 1
- 238000007912 intraperitoneal administration Methods 0.000 claims 1
- 238000001990 intravenous administration Methods 0.000 claims 1
- 230000007170 pathology Effects 0.000 claims 1
- 230000001629 suppression Effects 0.000 claims 1
- 238000012216 screening Methods 0.000 description 4
- 210000001056 activated astrocyte Anatomy 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 229940043355 kinase inhibitor Drugs 0.000 description 2
- 239000003757 phosphotransferase inhibitor Substances 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 210000002705 pancreatic stellate cell Anatomy 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462044675P | 2014-09-02 | 2014-09-02 | |
| US62/044,675 | 2014-09-02 | ||
| PCT/US2015/048202 WO2016036886A1 (en) | 2014-09-02 | 2015-09-02 | Compositions and methods for treating fibrosing disorders and cancer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2017527615A JP2017527615A (ja) | 2017-09-21 |
| JP2017527615A5 true JP2017527615A5 (https=) | 2018-10-04 |
Family
ID=55440352
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017531467A Pending JP2017527615A (ja) | 2014-09-02 | 2015-09-02 | 線維化疾患及び癌を治療するための組成物及び方法 |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US20180221369A1 (https=) |
| EP (1) | EP3188800A4 (https=) |
| JP (1) | JP2017527615A (https=) |
| WO (1) | WO2016036886A1 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017212021A1 (en) * | 2016-06-10 | 2017-12-14 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for the treatment of cancer |
| CN111107856A (zh) * | 2017-06-23 | 2020-05-05 | 耶鲁大学 | 增强基于t细胞的免疫疗法的效力的组合物和方法 |
| US20220218659A1 (en) * | 2019-05-25 | 2022-07-14 | Institute For Cancer Research D/B/A The Research Institute Of Fox Chase Cancer Center | PI3K/LYN-ACLY Signaling Inhibition |
| US11184294B1 (en) * | 2020-12-04 | 2021-11-23 | Capital One Services, Llc | Methods and systems for managing multiple content delivery networks |
| CN113350346B (zh) * | 2021-06-01 | 2023-06-27 | 广西医科大学第一附属医院 | 长春新碱在预防或治疗心肌纤维化中的应用 |
| CN117159520B (zh) * | 2023-08-17 | 2026-04-07 | 中国人民解放军海军军医大学第一附属医院 | 竹红菌甲素在制备抑制胰腺纤维化的药物中的应用 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040121952A1 (en) * | 1997-05-21 | 2004-06-24 | Children's Medical Center Corporation | Treatment of cancer |
| MX2009003306A (es) * | 2006-10-02 | 2009-04-23 | Medarex Inc | Anticuerpos humanos que se unen a cxcr4 y sus usos. |
| HUE035589T2 (en) * | 2010-05-26 | 2018-05-28 | Korea Inst Sci & Tech | An anti-inflammatory compound having an anti-tyrosine kinase inhibitory activity and a pharmaceutical composition containing it |
| US20130203817A1 (en) * | 2012-02-08 | 2013-08-08 | Vassa Informatics | Novel Inhibitors of LYN Kinase |
| US20140080772A1 (en) * | 2012-09-06 | 2014-03-20 | The Board Of Regents Of The University Of Texas System | Treatments for melanoma |
-
2015
- 2015-09-02 EP EP15837235.9A patent/EP3188800A4/en not_active Withdrawn
- 2015-09-02 WO PCT/US2015/048202 patent/WO2016036886A1/en not_active Ceased
- 2015-09-02 US US15/506,081 patent/US20180221369A1/en not_active Abandoned
- 2015-09-02 JP JP2017531467A patent/JP2017527615A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017527615A5 (https=) | ||
| JP2023098947A5 (https=) | ||
| KR102464774B1 (ko) | Pd-1 억제제를 투여함으로써 피부암을 치료하는 방법 | |
| PS | Possible role for tocilizumab, an anti–interleukin-6 receptor antibody, in treating cancer cachexia | |
| CN110536905B (zh) | 用于治疗肺癌的抗pd-1抗体 | |
| CA3066045A1 (en) | Il-1beta binding antibodies for use in treating cancer | |
| JP2020138972A (ja) | 疾患および障害の処置においてレナラーゼを制御する組成物および方法 | |
| JP2017507118A5 (https=) | ||
| JP2015529641A5 (https=) | ||
| BR112012025517B1 (pt) | Anticorpo monoclonal que reconhece fator inibidor de leucemia (lif) humano, linhagem de células de hibridoma e composição farmacêutica | |
| JP2018533591A5 (https=) | ||
| JP2024009886A (ja) | 好中球調節物質と免疫チェックポイントの調節物質の組み合わせを使用したがん処置 | |
| JP2021510697A5 (https=) | ||
| KR20210128021A (ko) | 종양성 질병들에 대한 치료 | |
| Singh Gautam et al. | Monoclonal antibodies for the management of central nervous system diseases: Clinical success and future strategies | |
| Esquerda-Canals et al. | Pharmacokinetic parameters and mechanism of action of an efficient anti-Aβ single chain antibody fragment | |
| CA2836473C (en) | Il-12 p40 monomer, monoclonal antibody against p40 homodimer and the combination of the two for autoimmune disease treatment | |
| Ashfaque et al. | Suppression to removal, an emerging therapeutic approach for AL amyloidosis: A comprehensive review with early human data and pharmacokinetics of CAEL-101 antibody | |
| JP7476450B2 (ja) | 免疫媒介性がん治療のための組成物及び方法 | |
| Poepel et al. | Neurological course of long-term surviving patients with SCLC and anti-Hu syndrome | |
| JP2017529364A5 (https=) | ||
| Liu et al. | Case report: Systemic sclerosis during neoadjuvant therapy for breast cancer in a 59-year-old woman | |
| JP2017528445A (ja) | 肝細胞癌の抗ｖｅｇｆｒ２抗体治療 | |
| KR102650186B1 (ko) | Api5 단백질에 특이적으로 결합하는 항체 | |
| KR20230124107A (ko) | 연수막 질환의 치료 방법 |